Literature DB >> 26171019

Expression of p16 and Survivin in gliomas and their correlation with cell proliferation.

Yansheng Gao1, Lingzhen Li2, Laijun Song3.   

Abstract

The survival rate of glioma patients is very low, and a lack of effective diagnostic techniques are available at present. The current study aimed to investigate the expression of p16 and Survivin and their association with proliferation and apoptosis in gliomas, as well as patient characteristics and prognosis. In total, 62 glioma specimens were surgically resected and pathologically confirmed at the Zhumadian Central Hospital (Zhumadian, China) between June 2008 and February 2014. Clinical data, including the gender and age of the patients, as well as the location, infiltration degree, size and pathological stage of the glioma, was collected. In order to evaluate the expression of p16 and Survivin in the gliomas, the Ki-67 labeling index was used to evaluate cell proliferation activity. The number of argyrophilic nucleolar organizer regions and the rate of cellular apoptosis was examined using the terminal deoxynucleotidyl transferase dUTP nick end labeling method. The results were analyzed using SPSS 14.0 statistical software. The positive rate of p16 gene expression in the gliomas was 46.77% (29 cases), and p16 gene expression was positively correlated with the differentiation status, tumor size and pre-operative symptoms. The positive rate of Survivin expression in the gliomas was 69.88% (58 cases), and Survivin expression was positively correlated with tumor size, differentiation status and clinical stage. The proliferation activity of the gliomas was enhanced with increasing p16 and Survivin expression, while apoptosis was inhibited. In conclusion, the overexpression of p16 and Survivin was closely associated with uncontrolled cell proliferation and the inhibition of apoptosis in gliomas. The combined analysis of the expression of p16 and Survivin in gliomas may provide guidance with respect to the clinical diagnosis, evaluation, treatment and prognosis of patients with glioma.

Entities:  

Keywords:  Survivin; glioma; p16; proliferation activity

Year:  2015        PMID: 26171019      PMCID: PMC4487136          DOI: 10.3892/ol.2015.3180

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis.

Authors:  Anna Parenti; Genesio Leo; Andrea Porzionato; Giovanni Zaninotto; Antonio Rosato; Vito Ninfo
Journal:  Hum Pathol       Date:  2006-01       Impact factor: 3.466

Review 2.  Role of a cell cycle regulator in hereditary and sporadic cancer.

Authors:  A Kamb
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

3.  [An evaluation for the function and significance concerned to alterations of P16 3D structure with gene mutation in esophageal squamous cell carcinoma].

Authors:  Li-hong Chen; Yi-wei Li; Lin-yun Gao; Jin-feng Liu
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2006-04

4.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.

Authors:  C Adida; P L Crotty; J McGrath; D Berrebi; J Diebold; D C Altieri
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

Review 5.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

6.  On the role of survivin as a stem cell biomarker of canine hair follicle and related tumours.

Authors:  Laura Bongiovanni; Francesca Di Diodoro; Leonardo Della Salda; Chiara Brachelente
Journal:  Vet Dermatol       Date:  2014-04       Impact factor: 1.589

Review 7.  Targeting survivin in cancer therapy.

Authors:  Marzia Pennati; Marco Folini; Nadia Zaffaroni
Journal:  Expert Opin Ther Targets       Date:  2008-04       Impact factor: 6.902

8.  Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis.

Authors:  Reiko Honda; Roman Körner; Erich A Nigg
Journal:  Mol Biol Cell       Date:  2003-05-29       Impact factor: 4.138

9.  Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells.

Authors:  Suvobroto Nandi; Ilya V Ulasov; Matthew A Tyler; Adam Quasar Sugihara; Luciana Molinero; Yu Han; Zeng B Zhu; Maciej S Lesniak
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Chemotherapy for gliomas in mainland China: An overview.

Authors:  Ke Sai; Qun-Ying Yang; Dong Shen; Zhong-Ping Chen
Journal:  Oncol Lett       Date:  2013-03-19       Impact factor: 2.967

View more
  5 in total

1.  Demethoxycurcumin was superior to temozolomide in the inhibition of the growth of glioblastoma stem cells in vivo.

Authors:  Liang Leng; Xiaojun Zhong; Guan Sun; Wen Qiu; Lei Shi
Journal:  Tumour Biol       Date:  2016-10-18

2.  p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.

Authors:  Roberta Soares Faccion; Paula Sabbo Bernardo; Giselle Pinto Faria de Lopes; Leonardo Soares Bastos; Cristina Lordello Teixeira; José Antonio de Oliveira; Priscila Valverde Fernandes; Luiz Gustavo Dubois; Leila Chimelli; Raquel Ciuvalschi Maia
Journal:  Cell Oncol (Dordr)       Date:  2018-01-26       Impact factor: 6.730

Review 3.  Evaluation of the use of therapeutic peptides for cancer treatment.

Authors:  Susan Marqus; Elena Pirogova; Terrence J Piva
Journal:  J Biomed Sci       Date:  2017-03-21       Impact factor: 8.410

4.  The reversal of MRP1 expression induced by low-frequency and low-intensity ultrasound and curcumin mediated by VEGF in brain glioma.

Authors:  Lei Yao; Zhen Zhang
Journal:  Onco Targets Ther       Date:  2019-05-13       Impact factor: 4.147

Review 5.  Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment.

Authors:  Christina Piperi; Kostas A Papavassiliou; Athanasios G Papavassiliou
Journal:  Cells       Date:  2019-11-06       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.